-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Biogen, Raises Price Target to $300

Benzinga·11/02/2026 14:29:00
Listen to the news
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.